TNF as a target of inflammation in rheumatoid arthritis

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 15, Issue 2, 2015, Pages 129-134

  Yamanaka, Hisashi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Cytokine; Inflammation; Molecular target; Receptor; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; CD20 ANTIBODY; CERTOLIZUMAB PEGOL; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 6 RECEPTOR; MATRIX METALLOPROTEINASE; METHOTREXATE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; AUTACOID;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); DAS28; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INFLAMMATION; INJECTION SITE REACTION; JOINT DESTRUCTION; META ANALYSIS (TOPIC); PNEUMOCYSTIS JIROVECI; PNEUMONIA; QUALITY OF LIFE; REMISSION; RHEUMATOID ARTHRITIS; TUBERCULOSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; DRUG DESIGN; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; RISK FACTOR; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG DESIGN; HUMANS; INFLAMMATION MEDIATORS; MOLECULAR TARGETED THERAPY; RISK FACTORS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84930516400     PISSN: 18715303     EISSN: 22123873     Source Type: Journal    
DOI: 10.2174/1871530315666150316121808     Document Type: Article

References (52)

1. [1] Smolen, J.S.; Han, C.; Bala, M.; Maini, R.N.; Kalden, J.R.; van der Heijde, D.; Breedveld, F.C.; Furst, D.E.; Lipsky, P.E.; ATTRACT Study Group. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum., 2005, 52, 1020-1030.
2. [2] Takeuchi, T.; Tatsuki, Y.; Nogami, Y.; Ishiguro, N.; Tanaka, Y.; Yamanaka, H.; Kamatani, N.; Harigai, M.; Ryu, J.; Inoue, K.; Kondo, H.; Inokuma, S.; Ochi, T.; Koike, T. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann. Rheum. Dis., 2008, 67, 189-194.
3. [3] Klareskog, L.; van der Heijde, D.; de Jager, JP.; Gough, A.; Kalden, J.; Malaise, M.; Martin Mola, E.; Pavelka, K.; Sany, J.; Settas, L.; Wajdula, J.; Pedersen, R.; Fatenejad, S.; Sanda, M.; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet, 2004, 363, 675-681.
4. [4] Koike, T.; Harigai, M.; Inokuma, S.; Ishiguro, N.; Ryu, J.; Takeuchi, T.; Tanaka, Y.; Yamanaka, H.; Fujii, K.; Yoshinaga, T.; Freundlich, B.; Suzukawa, M. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod. Rheumatol., 2011, 21, 343-351.
5. Singh, JA.; Wells, GA.; Christensen, R.; Tanjong Ghogomu, E.; Maxwell, L.; Macdonald, J.K.; Filippini, G.; Skoetz, N.; Francis, D.; Lopes, L.C.; Guyatt, G.H.; Schmitt, J.; La Mantia, L.; Weberschock, T.; Roos, J.F.; Siebert, H.; Hershan, S.; Lunn, M.P. ;Tugwell, P.; Buchbinder, R. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst. Rev., 2011, 16, CD008794.
6. [6] Takeuchi, T.; Miyasaka, N.; Inoue, K.; Abe, T.; Koike, T. RISING study. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod. Rheumatol., 2009, 19, 478-487.
7. [7] Koike, T.; Harigai, M.; Ishiguro, N.; Inokuma, S.; Takei, S.; Takeuchi, T.; Yamanaka, H.; Tanaka, Y. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod. Rheumatol., 2012, 22, 498-508.
8. [8] Dixon, W.G.; Hyrich, K.L.; Watson, K.D.; Lunt, M.; Galloway, J.; Ustianowski, A. BSRBR Control Centre Consortium.; Symmons, D.P.; BSR Biologics Register. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann. Rheum. Dis., 2010, 69, 522-528.
9. [9] Breedveld, F.C.; Weisman, M.H.; Kavanaugh, A.F.; Cohen, S.B.; Pavelka K.; van Vollenhoven, R.; Sharp, J.; Perez, J.L.; Spencer-Green, G.T. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum., 2006, 54, 26-37.
10. [10] Takeuchi, T.; Harigai, M.; Tanaka, Y.; Yamanaka, H.; Ishiguro, N.; Yamamoto, K.; Miyasaka, N.; Koike, T.; Kanazawa, M.; Oba, T.; Yoshinari, T.; Baker, D.; the GO-MONO study group. Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, doubleblind, placebo-controlled GO-MONO study through 24 weeks. Ann. Rheum. Dis., 2013, 72, 1488-1495.
11. [11] Tanaka, Y.; Harigai, M.; Takeuchi, T.; Yamanaka, H.; Ishiguro, N.; Yamamoto, K.; Miyasaka, N.; Koike, T.; Kanazawa, M.; Oba, T.; Yoshinari, T.; Baker, D.; GO-FORTH Study Group. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Ann. Rheum. Dis., 2012, 71, 817-824.
12. Singh, J.A.; Wells, G.A.; Christensen, R.; Tanjong Ghogomu, E.; Maxwel, L.; Macdonald, J.K.; Filippini, G.; Skoetz, N.; Francis, D.; Lopes, L.C.; Guyatt, G.H.; Schmitt, J.; La Mantia, L.; Weberschock, T.; Roos, J.F.; Siebert, H.; Hershan, S.; Lunn, M.P.; Tugwell, P.; Buchbinder, R. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev., 2011, 16, CD008794.
13. [13] Nam, J.; Emery, P. Aspects of TNF inhibitor therapy in rheumatoid arthritis. Mod Rheumatol., 2010, 20, 325-330.
14. [14] Strand, V.; Singh, J.A.; Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs, 2010, 70, 121-145.
15. [15] Kameda, H.; Ueki, Y.; Saito, K.; Nagaoka, S.; Hidaka, T.; Atsumi, T.; Tsukano, M.; Kasama, T.; Shiozawa, S.; Tanaka, Y.; Takeuchi, T. Japan Biological Agent Study Integrated Consortium. Etanercept (ETN) with methotrexate (methotrexate) is better than ETN monotherapy in patients with active rheumatoid arthritis despite methotrexate therapy: a randomized trial. Mod. Rheumatol., 2010, 20, 531-538.
16. [16] Kuriya, B.; Arkema, E.V.; Bykerk, V.P.; Keystone, EC. Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission. Ann. Rheum. Dis., 2010, 69, 1298-1304.
17. [17] Wiens, A.; Venson, R.; Correr, C.J.; Otuki, M.F.; Pontarolo, R. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy, 2010, 30, 339-353.
18. Singh, J.A.; Christensen, R.; Wells, G.A.; Suarez-Almazor, M.E.; Buchbinder, R.; Lopez-Olivo, M.A.; Tanjong Ghogomu, E.; Tugwell, P. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst. Rev., 2009, 7, CD007848.
19. [19] Alivernini, S.; Laria, A.; Gremese, E.; Zoli, A.; Ferraccioli, G. ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature. Arthritis Res, Ther., 2009, 11, R163.
20. [20] Takeuchi, T.; Miyasaka, N.; Tatsuki, Y.; Yano, T.; Yoshinari, T.; Abe, T.; Koike, T. Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann. Rheum. Dis., 2011, 70, 1208-1215.
21. [21] Potter, C.; Cordell, H.J.; Barton, A.; Daly, A.K.; Hyrich, K.L.; Mann, D.A.; Morgan, A.W.; Wilson, A.G.; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS), Isaacs, J.D. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways. Ann. Rheum. Dis., 2010, 69, 1315-1320.
22. [22] Tan, R.J.; Gibbons, L.J.; Potter, C.; Hyrich, K.L.; Morgan, A.W.; Wilson, A.G.; Isaacs, J.D.; BRAGGSS.; Barton, A. Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment.Ann. Rheum. Dis., 2010, 69, 1029-1035.
23. [23] Cui, J.; Saevarsdottir, S.; Thomson, B.; Padyukov, L.; van der Helm-van Mil, A.H.; Nititham, J.; Hughes, L.B.; de Vries, N.; Raychaudhuri, S.; Alfredsson, L.; Askling, J.; Wedren, S.; Ding, B.; Guiducci, C.; Wolbink, G.J.; Crusius, J.B.; van der Horst-Bruinsma, I.E.; Herenius, M.; Weinblatt, M.E.; Shadick, N.A.; Worthington, J.; Batliwalla, F.; Kern, M.; Morgan, A.W.; Wilson, A.G.; Isaacs, J.D.; Hyrich, K.; Seldin, M.F.; Moreland, L.W.; Behrens, T.W.; Allaart, C.F.; Criswell, L.A.; Huizinga, T.W.; Tak, P.P.; Bridges, S.L.; Toes, R.E.; Barton, A.; Klareskog, L.; Gregersen, P.K.; Karlson, E.W.; Plenge, R.M. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum., 2010, 62, 1849-1861.
24. [24] Mavragani, C.P.; La, D.T.; Stohl, W.; Crow, M.K. Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort. Arthritis Rheum., 2010, 62, 392-401
25. [25] Hassan, B.; Maxwell, J.R.; Hyrich, K.L.; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate.; Barton, A.; Worthington, J.; Isaacs, J.D.; Morgan, A.W.; Wilson, A.G. Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis. Rheumatology (Oxford), 2010, 49, 43-47.
26. [26] Marotte, H.; Miossec, P. Biomarkers for prediction of TNFalpha blockers response in rheumatoid arthritis.Joint Bone Spine, 2010, 77, 297-305.
27. [27] Salmon-Ceron, D.; Tubach, F.; Lortholary, O.; Chosidow, O.; Bretagne, S.; Nicolas, N.; Cuillerier, E.; Fautrel, B.; Michelet, C.; Morel, J.; Puechal, X.; Wendling, D.; Lemann, M.; Ravaud, P.; Mariette, X.; RATIO group. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann. Rheum. Dis., 2011, 70, 616-623.
28. [28] Nam, J.L.; Winthrop, K.L.; van Vollenhoven, R.F.; Pavelka, K.; Valesini, G.; Hensor, E.M.; Worthy, G.; Landewe, R.; Smolen, J.S.; Emery, P.; Buch, M.H. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann. Rheum. Dis., 2010, 69, 976-986.
29. Singh, J.A.; Wells, G.A.; Christensen, R.; Tanjong Ghogomu, E.; Maxwell, L.; Macdonald, J.K.; Filippini, G.; Skoetz, N.; Francis, D.; Lopes, L.C.; Guyatt, G.H.; Schmitt, J.; La Mantia, L.; Weberschock, T.; Roos, J.F.; Siebert, H.; Hershan, S.; Lunn, M.P.; Tugwell, P.; Buchbinder, R. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst. Rev., 2011, 16, CD00879.
30. [30] Luzi, G.; Lagana, B.; Salemi, S.; Di Rosa, R.Are glucocorticoids a consistent risk factor for infections in rheumatoid arthritis patients under treatment with methotrexate and etanercept? Clin. Ter.,2009, 160, 121-123.
31. [31] Furst, D.E. The risk of infections with biologic therapies for rheumatoid arthritis. Semin. Arthritis Rheum., 2010, 39, 327-346.
32. [32] Salemi, S.; Picchianti-Diamanti, A.; Germano, V.; Donatelli, I.; Di Martino, A.; Facchini, M.; Nisini, R.; Biselli, R.; Ferlito, C.; Podesta, E.; Cappella, A.; Milanetti, F.; Rossi, F.; Amodeo, R.; Tabacco, F.; Di Rosa, R.; Lagana, B.; D Amelio, R. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity. Clin. Immunol., 2010, 134, 113-120.
33. [33] Komano, Y.; Harigai, M.; Koike, R.; Sugiyama, H.; Ogawa, J.; Saito, K.; Sekiguchi, N.; Inoo, M.; Onishi, I.; Ohashi, H.; Amamoto, F.; Miyata, M.; Ohtsubo, H.; Hiramatsu, K.; Iwamoto, M.; Minota, S.; Matsuoka, N.; Kageyama, G.; Imaizumi, K.; Tokuda, H.; Okochi, Y.; Kudo, K.; Tanaka, Y.; Takeuchi, T.; Miyasaka, N. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients.Arthritis Rheum., 2009, 61, 305-312.
34. [34] Kameda, H.; Tokuda, H.; Sakai, F.; Johkoh, T.; Mori, S.; Yoshida, Y.; Takayanagi, N.; Taki, H.; Hasegawa, Y.; Hatta, K.; Yamanaka, H.; Dohi, M.; Hashimoto, S.; Yamada, H.; Kawai, S.; Takeuchi, T.; Tateda, K.; Goto, H. Clinical and radiological features of acuteonset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents: importance of pneumocystis pneumonia in Japan revealed by a multicenter study. Intern. Med., 2011, 50, 305-313.
35. [35] Mori, S.; Cho, I.; Ichiyasu, H.; Sugimoto, M. Asymptomatic carriage of Pneumocystis jiroveci in elderly patients with rheumatoid arthritis in Japan: a possible association between colonization and development of Pneumocystis jiroveci pneumonia during low-dose methotrexate therapy.Mod. Rheumatol., 2008, 18, 240-246.
36. [36] Mori, S.; Cho, I.; Sugimoto, M. A. Followup study of asymptomatic carriers of Pneumocystis jiroveci during immunosuppressive therapy for rheumatoid arthritis.J. Rheumatol., 2009, 36, 1600-1605.
37. [37] Wissmann, G.; Morilla, R.; Martin-Garrido, I.; Friaza, V.; Respaldiza, N.; Povedano, J.; Praena-Fernandez, J.M.; Montes-Cano, M.A.; Medrano, F.J.; Goldani, L.Z.; de la Horra, C.; Varela, J.M.; Calderon, E.J.Pneumocystis jirovecii colonization in patients treated with infliximab.Eur. J. Clin. Invest., 2011, 41, 343-348.
38. [38] Louie, G.H.; Wang, Z.; Ward, M.M. Trends in hospitalizations for Pneumocystis jiroveci pneumonia among patients with rheumatoid arthritis in the US: 1996-2007. Arthritis Rheum., 2010, 62, 3826-3827.
39. [39] Lopez-Olivo, M.A.; Tayar, J.H.; Martinez-Lopez, JA.; Pollono, E.N.; Cueto, J.P.; Gonzales-Crespo, M.R.; Fulton, S.; Suarez-Almazor, M.E. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA, 2012, 308, 898-908.
40. [40] Mariette, X.; Tubach, F.; Bagheri, H.; Bardet, M.; Berthelot, J.M.; Gaudin, P.; Heresbach, D.; Martin, A.; Schaeverbeke, T.; Salmon, D.; Lemann, M.; Hermine, O.; Raphael, M, ; Ravaud, P. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry.Ann. Rheum. Dis., 2010, 69, 400-408.
41. [41] Wolfe, F.; Michaud, K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum., 2007, 56, 1433-1439.
42. [42] Khraishi, M. Comparative overview of safety of the biologics in rheumatoid arthritis. J. Rheumatol. Suppl., 2009, 82, 25-32
43. [43] Carroll, M.B.; Forgione, M.A. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin. Rheumatol., 2010, 29, 1021-1029.
44. [44] Caporali, R.; Bobbio-Pallavicini, F.; Atzeni, F.; Sakellariou, G.; Caprioli, M.; Montecucco, C.; Sarzi-Puttini, P.; Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res. (Hoboken), 2010, 62, 749-754.
45. [45] Vassilopoulos, D.; Apostolopoulou, A.; Hadziyannis, E.; Papatheodoridis, G.V.; Manolakopoulos, S.; Koskinas, J.; Manesis, E.K.; Archimandritis, A.I. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.Ann. Rheum. Dis., 2010, 69, 1352-1355
46. [46] Giannitti, C.; Benucci, M.; Caporali, R.; Manganelli, S.; Bellisai, F.; Sebastiani, G.D.; Galeazzi, M. Efficacy and safety of anti-TNFalpha therapy combined with cyclosporine A in patients with rheumatoid arthritis and concomitant hepatitis C virus infection. Int. J. Immunopathol. Pharmacol.,2009, 22, 543-546.
47. [47] Tanaka, E.; Hoshi, D.; Igarashi, A.; Inoue, E.; Shidara, K.; Sugimoto, N.; Sato, E.; Seto, Y.; Nakajima, A.; Momohara, S.; Taniguchi, A.; Tsutani, K.; Yamanaka, H. Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA. Mod. Rheumatol., 2013, 23, 742-751.
48. [48] van Vollenhoven, R.F. Rheumatologists, take heart! We may be doing something right. Arthritis Res. Ther., 2008, 10, 105.
49. [49] Nakajima, A.; Saito, K.; Kojima, T.; Amano, K.; Yoshio, T.; Fukuda, W.; Inoue, E.; Taniguchi, A.; Momohara, S.; Minota, S.; Takeuchi, T.; Ishiguro, N.; Tanaka, Y.; Yamanaka, H.No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan. Mod. Rheumatol., 2013, 23, 945-952.
50. [50] Tanaka, Y.; Takeuchi, T.; Mimori, T.; Saito, K.; Nawata, M.; Kameda, H.; Nojima, T.; Miyasaka, N.; Koike, T.; and RRR study investigators. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study.Ann. Rheum. Dis., 2010, 69, 1286-1291.
51. [51] Smolen, J.S.; Nash, P.; Durez, P.; Hall, S.; Ilivanova, E.; Irazoque-Palazuelos, F.; Miranda, P.; Park, M.C.; Pavelka, K.; Pedersen, R.; Szumski, A.; Hammond, C.; Koenig, A.S.; Vlahos, B. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet, 2013, 381, 918-29.
52. [52] Yoshida, K.; Sung, Y.K.; Kavanaugh, A.; Bae, S.C.; Weinblatt, M.E.; Kishimoto, M.; Matsui, K.; Tohma, S.; Solomon, D.H.; Biologic discontinuation studies: a systematic review of methods. Ann. Rheum. Dis., 2014, 73, 595-599